Galen sales double in third quarter

Northern Ireland-based pharmaceuticals group Galen toasted the addition of a string of new drugs today after third quarter results showed sales had more than doubled.

The group, which was the subject of a short-lived takeover approach last month, said the US launch of its pre-menstrual syndrome treatment Sarafem and a handful of new women’s health products had helped push sales up 117% to $135.7m (€119m).